Latest From PAVmed Inc.
Starts & Stops: Boston Scientific Launches New Lotus TAVR Trial, Medtronic Starts Study Of SynchroMed II Pain Pump
Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by MedDeviceTracker. This edition covers trial announcements from Jan. 7 through Jan. 27, including announcements from Medtronic, QT Vascular, Boston Scientific, and Shockwave.
Device manufacturer PAVmed is planning to resubmit a 510(k) for its CarpX product to treat carpal tunnel syndrome after US FDA said it couldn’t reach a consensus on approval.
In a busy month, MD Anderson also partners with Ipsen on an unspecified cancer drug and licenses poziotinib IP to Spectrum. Using IP from UCLA, Bloom launches with focus on neuroprotective epilepsy therapies.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
- Implantable Devices
- Surgical Equipment & Devices
- Therapeutic Areas
- Infectious & Viral Diseases
- Musculoskeletal & Connective Tissue Disorders
- North America
- Parent & Subsidiaries
- PAVmed Inc.
- Senior Management
Lishan Aklog, MD, Chmn. & CEO
Dennis M McGrath, EVP, CFO
Brian J deGuzman, MD, CMO
- Contact Info
Phone: (212) 949-9319
One Grand Central Pl., Ste. 4600
New York, NY 10165
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.